99 related articles for article (PubMed ID: 23627841)
1. Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice.
Hughes KH; Wijekoon EP; Valcour JE; Chia EW; McGuire JJ
Can J Physiol Pharmacol; 2013 Apr; 91(4):295-305. PubMed ID: 23627841
[TBL] [Abstract][Full Text] [Related]
2. Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice.
Chia E; Kagota S; Wijekoon EP; McGuire JJ
BMC Pharmacol; 2011 Sep; 11():10. PubMed ID: 21955547
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery.
Matsumoto T; Ishida K; Taguchi K; Kobayashi T; Kamata K
Peptides; 2009 Sep; 30(9):1729-34. PubMed ID: 19540892
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Nitric Oxide Synthase Activation via Protease-Activated Receptor 2 Is Involved in the Preserved Vasodilation in Aortas from Metabolic Syndrome Rats.
Maruyama K; Kagota S; McGuire JJ; Wakuda H; Yoshikawa N; Nakamura K; Shinozuka K
J Vasc Res; 2015; 52(4):232-43. PubMed ID: 26760532
[TBL] [Abstract][Full Text] [Related]
5. Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2.
McGuire JJ; Dai J; Andrade-Gordon P; Triggle CR; Hollenberg MD
J Pharmacol Exp Ther; 2002 Dec; 303(3):985-92. PubMed ID: 12438518
[TBL] [Abstract][Full Text] [Related]
6. Age-related changes to vascular protease-activated receptor 2 in metabolic syndrome: a relationship between oxidative stress, receptor expression, and endothelium-dependent vasodilation.
Maruyama K; Kagota S; McGuire JJ; Wakuda H; Yoshikawa N; Nakamura K; Shinozuka K
Can J Physiol Pharmacol; 2017 Apr; 95(4):356-364. PubMed ID: 28103056
[TBL] [Abstract][Full Text] [Related]
7. Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.
Kagota S; Maruyama K; Wakuda H; McGuire JJ; Yoshikawa N; Nakamura K; Shinozuka K
Vascul Pharmacol; 2014 Oct; 63(1):46-54. PubMed ID: 25109437
[TBL] [Abstract][Full Text] [Related]
8. Effect of PAR2 in regulating TNF-α and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice.
Park Y; Yang J; Zhang H; Chen X; Zhang C
Basic Res Cardiol; 2011 Jan; 106(1):111-23. PubMed ID: 20972877
[TBL] [Abstract][Full Text] [Related]
9. Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice.
Hennessey JC; McGuire JJ
PLoS One; 2013; 8(2):e55965. PubMed ID: 23409098
[TBL] [Abstract][Full Text] [Related]
10. Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive mice.
McGuire JJ; Van Vliet BN; Giménez J; King JC; Halfyard SJ
Pflugers Arch; 2007 Jul; 454(4):535-43. PubMed ID: 17318644
[TBL] [Abstract][Full Text] [Related]
11. Blood pressures, heart rate and locomotor activity during salt loading and angiotensin II infusion in protease-activated receptor 2 (PAR2) knockout mice.
McGuire JJ; Van Vliet BN; Halfyard SJ
BMC Physiol; 2008 Oct; 8():20. PubMed ID: 18939990
[TBL] [Abstract][Full Text] [Related]
12. Impairment of Protease-Activated Receptor 2-Induced Relaxation of Aortas of Aged Spontaneously Hypertensive Rat.
Ando M; Matsumoto T; Kobayashi S; Iguchi M; Taguchi K; Kobayashi T
Biol Pharm Bull; 2018; 41(5):815-819. PubMed ID: 29709920
[TBL] [Abstract][Full Text] [Related]
13. Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice.
Kagota S; Chia E; McGuire JJ
Br J Pharmacol; 2011 Sep; 164(2):358-71. PubMed ID: 21426317
[TBL] [Abstract][Full Text] [Related]
14. Endothelium dysfunction in hind limb arteries of male Zucker Diabetic-Sprague Dawley rats.
Wang AN; Carlos J; Singh KK; Fraser GM; McGuire JJ
Biochem Pharmacol; 2022 Dec; 206():115319. PubMed ID: 36279920
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying impairment of endothelium-dependent relaxation by fetal bovine serum in organ-cultured rat mesenteric artery.
Morita T; Okada M; Hara Y; Yamawaki H
Eur J Pharmacol; 2011 Oct; 668(3):401-6. PubMed ID: 21854767
[TBL] [Abstract][Full Text] [Related]
16. Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo.
Kawabata A; Kanke T; Yonezawa D; Ishiki T; Saka M; Kabeya M; Sekiguchi F; Kubo S; Kuroda R; Iwaki M; Katsura K; Plevin R
J Pharmacol Exp Ther; 2004 Jun; 309(3):1098-107. PubMed ID: 14976227
[TBL] [Abstract][Full Text] [Related]
17. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo.
Scotland RS; Madhani M; Chauhan S; Moncada S; Andresen J; Nilsson H; Hobbs AJ; Ahluwalia A
Circulation; 2005 Feb; 111(6):796-803. PubMed ID: 15699263
[TBL] [Abstract][Full Text] [Related]
18. Basal nitric oxide modulates vascular effects of a peptide activating protease-activated receptor 2.
Cicala C; Morello S; Vellecco V; Severino B; Sorrentino L; Cirino G
Cardiovasc Res; 2003 Nov; 60(2):431-7. PubMed ID: 14613873
[TBL] [Abstract][Full Text] [Related]
19. 2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.
McGuire JJ; Saifeddine M; Triggle CR; Sun K; Hollenberg MD
J Pharmacol Exp Ther; 2004 Jun; 309(3):1124-31. PubMed ID: 14976230
[TBL] [Abstract][Full Text] [Related]
20. Essential role of bone marrow for microvascular endothelial and metabolic functions in mice.
Nakajima S; Ohashi J; Sawada A; Noda K; Fukumoto Y; Shimokawa H
Circ Res; 2012 Jun; 111(1):87-96. PubMed ID: 22550140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
